Demographics of patients on the GIPAP
| . | All . | Africa and Middle East . | Asia Pacific . | Eastern Europe, Central Asia . | Latin America . | South Asia . |
|---|---|---|---|---|---|---|
| Years | 2001-2019 | 2001-2019 | 2001-2019 | 2001-2019 | 2001-2019 | 2003-2019 |
| Patients, n | 14c408 | 5904 | 850 | 3141 | 2629 | 1884 |
| Age, median [range] | 39 [1-93] | 38 [1-93] | 36 [3-88] | 42 [1-85] | 40 [2-87] | 37 [2-92] |
| Male, n | 7c739 (55.8%) | 3307 (57.2%) | 456 (57.1%) | 1464 (48.6%) | 1410 (55.7%) | 1102 (62.7%) |
| Phase, n | ||||||
| Accelerated | 932 (6.7%) | 268 (4.6%) | 56 (7.0%) | 420 (13.9%) | 140 (5.5%) | 48 (2.7%) |
| Blast crisis | 144 (1.0%) | 42 (0.7%) | 25 (3.1%) | 29 (1.0%) | 22 (0.9%) | 26 (15%) |
| Chronic | 12c581 (91.7%) | 5363 (92.8%) | 686 (86.0%) | 2540 (84.3%) | 2356 (93.1%) | 1636 (93.1%) |
| Remission | 177 (1.3%) | 107 (1.9%) | 1 (0.1%) | 20 (0.7%) | 8 (0.3%) | 41 (2.3%) |
| Treatment, n | ||||||
| Bosutinib | 118 (0.8%) | 49 (0.3%) | 49 (6.1%) | 0 (0.0%) | 6 (0.0%) | 14 (0.1%) |
| Imatinib | 13c225 (91.8%) | 5632 (97.4%) | 561 (69.8%) | 2937 (97.2%) | 2461 (97.7%) | 1634 (92.5%) |
| Ponatinib | 303 (2.1%) | 27 (0.3%) | 145 (17.8%) | 46 (0.8%) | 7 (0.2%) | 78 (3.9%) |
| Dasatinib | 430 (3.0%) | 178 (1.7%) | 88 (6.3%) | 25 (0.4%) | 56 (1.2%) | 83 (1.6%) |
| Nilotinib | 332 (2.3%) | 18 (0.2%) | 7 (0.0%) | 133 (1.7%) | 99 (0.8%) | 75 (1.9%) |
| . | All . | Africa and Middle East . | Asia Pacific . | Eastern Europe, Central Asia . | Latin America . | South Asia . |
|---|---|---|---|---|---|---|
| Years | 2001-2019 | 2001-2019 | 2001-2019 | 2001-2019 | 2001-2019 | 2003-2019 |
| Patients, n | 14c408 | 5904 | 850 | 3141 | 2629 | 1884 |
| Age, median [range] | 39 [1-93] | 38 [1-93] | 36 [3-88] | 42 [1-85] | 40 [2-87] | 37 [2-92] |
| Male, n | 7c739 (55.8%) | 3307 (57.2%) | 456 (57.1%) | 1464 (48.6%) | 1410 (55.7%) | 1102 (62.7%) |
| Phase, n | ||||||
| Accelerated | 932 (6.7%) | 268 (4.6%) | 56 (7.0%) | 420 (13.9%) | 140 (5.5%) | 48 (2.7%) |
| Blast crisis | 144 (1.0%) | 42 (0.7%) | 25 (3.1%) | 29 (1.0%) | 22 (0.9%) | 26 (15%) |
| Chronic | 12c581 (91.7%) | 5363 (92.8%) | 686 (86.0%) | 2540 (84.3%) | 2356 (93.1%) | 1636 (93.1%) |
| Remission | 177 (1.3%) | 107 (1.9%) | 1 (0.1%) | 20 (0.7%) | 8 (0.3%) | 41 (2.3%) |
| Treatment, n | ||||||
| Bosutinib | 118 (0.8%) | 49 (0.3%) | 49 (6.1%) | 0 (0.0%) | 6 (0.0%) | 14 (0.1%) |
| Imatinib | 13c225 (91.8%) | 5632 (97.4%) | 561 (69.8%) | 2937 (97.2%) | 2461 (97.7%) | 1634 (92.5%) |
| Ponatinib | 303 (2.1%) | 27 (0.3%) | 145 (17.8%) | 46 (0.8%) | 7 (0.2%) | 78 (3.9%) |
| Dasatinib | 430 (3.0%) | 178 (1.7%) | 88 (6.3%) | 25 (0.4%) | 56 (1.2%) | 83 (1.6%) |
| Nilotinib | 332 (2.3%) | 18 (0.2%) | 7 (0.0%) | 133 (1.7%) | 99 (0.8%) | 75 (1.9%) |
This table describes the distribution and demographics of patients enrolled in the GIPAP program across various regions of the world. Also, the phase of disease at diagnosis and percentage of second- and third-generation TKIs is provided.